Prostate cancer awareness gets a huge boost on Super Bowl Sunday when a new ad featuring several of the NFL’s greatest all-time players premieres during the most watched football game of the year.
Add Yahoo as a preferred source to see more of our stories on Google. The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common ...
Life Line Prostate Cancer Screening Program offers comprehensive PSA testing for men 50+ through over 14,000 convenient locations nationwide. With packages starting at $159 and specialized men's ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
Prostate cancer is common. About 200 in every 1,000 Australian men will be told they have prostate cancer by age 85. But the chance of dying from it is much lower: around 18 in 1,000 cases.
LR+ = positive likelihood ratio; LR– = negative likelihood ratio; PSA = prostate-specific antigen; PSE = EpiSwitch prostate screening. *—Binary PSA is defined as a simple test using a fixed cutoff ...
Add Yahoo as a preferred source to see more of our stories on Google. New research has found 'wide variation' in the use of prostate cancer testing across the UK. (Getty Images) A new at-home spit ...
Current prostate specific antigen (PSA) testing "may not effectively target testing to those most likely to benefit, raising concerns about overtesting" warn researchers from the University of Oxford ...
A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer is ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized ...
(Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results